Granules India has reported results for third quarter ended December 31, 2012.
The company, on the consolidated basis, has reported 27.28% fall in its net profit at Rs 5.81 crore for the quarter ended December 31, 2012 as compared to Rs 7.99 crore for the same quarter in the previous year. Total income of the company has increased by 5.12% at Rs 195.22 crore for quarter under review as compared to Rs 185.72 crore for the quarter ended December 31, 2011.
Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1800.65 |
| Dr. Reddys Lab | 1277.05 |
| Cipla | 1372.75 |
| Zydus Lifesciences | 1078.40 |
| Lupin | 2277.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: